Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics.
- 1 September 1997
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 54 (6) , 685-693
- https://doi.org/10.1016/s0006-2952(97)00222-0
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- TcO(PnAO-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reductionJournal of Medicinal Chemistry, 1994
- Bioreductive metabolism of AF-2 [2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles: Implications for use as hypoxic cell markersBiochemical Pharmacology, 1993
- Imaging Ischemic Tissue at Risk of Infarction during StrokeJournal of Cerebral Blood Flow & Metabolism, 1993
- Intratumoral pO2 predicts survival in advanced cancer of the uterine cervixRadiotherapy and Oncology, 1993
- Imaging of hypoxia in human tumors with [F-18]fluoromisonidazoleInternational Journal of Radiation Oncology*Biology*Physics, 1992
- The Reduction Potential of Benzyl Viologen: An Important Reference Compound for Oxidant/Radical Redox CouplesFree Radical Research Communications, 1991
- Reduction Potentials of One-Electron Couples Involving Free Radicals in Aqueous SolutionJournal of Physical and Chemical Reference Data, 1989
- Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxiaInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Hypoxic Sensitizers — Implications for Radiation TherapyNew England Journal of Medicine, 1979
- Misonidazole—A drug for trial in radiotherapy and oncologyInternational Journal of Radiation Oncology*Biology*Physics, 1979